Ronald Blue Trust, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Ronald Blue Trust, Inc.
- $7.7 Billion
- Q4 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 332 shares of APLS stock, worth $8,104. This represents 0.0% of its overall portfolio holdings.
Number of Shares
332
Previous 862
61.48%
Holding current value
$8,104
Previous $27,000
62.96%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$298 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$290 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$288 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$245 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$235 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.68B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...